deltatrials
Completed PHASE4 NCT00777764

The Safety and Utility of Skin Testing With XOLAIR® (Omalizumab) and Placebo Omalizumab (Formulation Excipients)

Sponsor: Genentech, Inc.

Conditions Asthma Healthy
Interventions Cohort 2 Cohort I
Updated 9 times since 2017 Last updated: May 16, 2017 Started: Aug 31, 2008 Primary completion: Apr 30, 2009 Completion: Apr 30, 2009

Listed as NCT00777764, this PHASE4 trial focuses on Asthma and Healthy and remains completed. Sponsored by Genentech, Inc., it has been updated 9 times since 2008, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Change History

9 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE4

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE4

  3. Jan 2023 — Jul 2024 [monthly]

    Completed PHASE4

  4. Dec 2022 — Jan 2023 [monthly]

    Completed PHASE4

  5. Jan 2021 — Dec 2022 [monthly]

    Completed PHASE4

▶ Show 4 earlier versions

  1. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE4

  2. Jul 2017 — Jun 2018 [monthly]

    Completed PHASE4

  3. Feb 2017 — Jul 2017 [monthly]

    Completed PHASE4

  4. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE4

    First recorded

Aug 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Genentech, Inc.
Data source: Genentech, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.